Zurich-Schlieren, Switzerland, 7 September 2023
We are thrilled to announce that TOPADUR Pharma AG has once again been recognized as one of Switzerland's top 25 scale-up companies.
This achievement is a demonstration to our team's dedication and our partners' support.
We are grateful for this recognition and remain committed to pushing the boundaries of innovation in the years to come.
Please check out the link below.
TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds.
Read moreTOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.
Read moreDiabetic Retinopathy is a severe complication of diabetes and a cause of blindness in adults.
Read more